Liver disease and diabetes: Association, pathophysiology, and management

Diabetes Research and Clinical Practice

Volumn 104, Issue 1, 2014, Pages 53-62

  Ahmadieh, Hala ^a   Azar, Sami T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Diabetes mellitus; Liver disease; Liver transaminases; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

AUTOIMMUNE HEPATITIS; DISEASE ASSOCIATION; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LOW CALORY DIET; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; REVIEW; SURVIVAL RATE; COMPLICATION; DIABETES MELLITUS; LIVER DISEASES;

DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; LIVER DISEASES;

EID: 84898546399     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.003     Document Type: Review

References (101)

1. Guariguata L, Whiting DR, Hambleton I, Beagle J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Research and Clinical Practice. Available online 1 December 2013. http://dx.doi.org/10.1016/j.diabres.2013.11.002.
2. cdcinfo@cdc.gov. Centers for Disease Control and Prevention. National Center for Health Statistics Accessed 2012.
3. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Thoraval FR.;1; The burden of liver disease in Europe: a review of available epidemiological data. The European Association for the Study of the Liver 2013; 978-2-8399-1176-4.
4. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
5. Balkau B., Eschwege E., Ducimetiere P., Richard J.L., Warnet J.M. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol 1991, 44:465-474.
6. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999, 22:756-761.
7. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999, 107:2S-9S.
8. Mehta S.H., Brancati F.L., Sulkowski M.S., Strathdee S.A., Szklo M., Thomas D.L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000, 133:592-599.
9. Mason A.L., Lau J.Y., Hoang N., Qian K., Alexander G.J., Xu L., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 29:328-333.
10. Sangiorgio L., Attardo T., Gangemi R., Rubino C., Barone M., Lunetta M. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2000, 48:147-151.
11. Caronia S., Taylor K., Pagliaro L., Carr C., Palazzo U., Petrik J., et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999, 30:1059-1063.
12. Ozyilkan E., Erbas T., Simsek H., Telatar F., Kayhan B., Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern. Med. 1994, 235:283-284.
13. Gray H., Wreghitt T., Stratton I.M., Alexander G.J., Turner R.C., O'Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function test. Diabet. Med. 1995, 12:244-249.
14. Simó R., Hernández C., Genesca' J., Jardí R., Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996, 19:998-1000.
15. Rudoni S., Petit J.M., Bour J.B., Aho L.S., Castaneda A., Vaillant G., Verges B., Brun J.M. HCV infection and diabetes mellitus: influence of the use of finger stick devices on nosocomial transmission. Diabetes Metab. 1999, 25:502-505.
16. Honeyman M.C., Stone N.L., Harrison L.C. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA2: potential for mimicry with rotavirus and other envirommental agents. Mol. Med. 1998, 4:231-239.
17. Strassburg C.P., Obermayer-Straaub P., Manns M.P. Autoimmunity in hepatitis C and D virus infection. J Viral Hepatitis 1996, 3:49-59.
18. Hieronimus S., Fredenrich A., Tran A., Benzaken S., Fenichel P. Antibodies to GAD in chronic hepatitis C patients (Letter). Diabetes Care 1997, 20:1044.
19. Ando H., Nagai Y., Yokohama M., Takamura T., Kobayashi K. Antibodies to GAD in diabetic patients with chronic hepatitis C (Letter). Diabet Med 1998, 15:797.
20. Harman-Boehm I., Zingman L., Hilzenrat N. No evidence for anti-islet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection (Letter). Hepatology 1999, 30:342.
21. Betterle C., Fabris P., Zanchetta R., Pedini B., Tositti G., Bosi E., et al. Autoimmunity againts pancreatic islets and other tissues before and after interferon alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000, 23:1177-1181.
22. Laskus T., Radkowski M., Wang L.F., Vargas H., Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative- strand viral RNA in various tissues. Hepatology 1998, 28:1398-1401.
23. Lecube A., Hernandez C., Genesca J., Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006, 29:1096101.
24. Lecube A., Hernandez C., Genesca J., Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 2006, 29:11409.
25. Fabris C., Soardo G., Falleti E., Toniutto P., Vitulli D., Federico E., et al. Relationship among hepatic inflammatory changes, circulating levels of citokines, and response to IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 1998, 18:705-709.
26. Kallinowski B., Haseroth K., Marinos G., Hanck C., Stremmel W., Theilmann L., et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998, 111:269-277.
27. Zylberberg H., Rimaniol A.C., Pol S., Masson A., De Groote D., Berthelot P., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999, 30:185-191.
28. Itoh Y., Okanoue T., Ohnishi N., Sakamoto M., Nishioji K., Nakagawa Y., et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1999, 94:1332-1340.
29. Dumoulin F.L., Wennrich U., Nischalke H.D., Leifeld L., Fisher H.P., Sauerbruch T., et al. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. J. Hum. Virol. 2001, 4:195-199.
30. Rotter V., Nagaev I., Smith U. Interleukin- 6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin resistant subjects. J Biol Chem 2003, 278:45777-45784.
31. Klover P.J., Zimmers T.A., Koniaris L.G., Mooney R.A. Chronic exposure to interleukin- 6 causes hepatic insulin resistance. Diabetes. 2003, 52(11):2784-2789.
32. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002, 34:255-262.
33. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. American J. Med. 1999, 107:450-455.
34. Dixon J., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
35. Trombetta M., Spiazzi G., Zoppini G., Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005, 22(Suppl. 2):24-27.
36. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
37. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
38. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol. 1989, 20:594-598.
39. Itoh S., Yougel T., Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am. J. Gastroenterol. 1987, 82:650-654.
40. Diehl A.M., Goodman Z., Ishak K.G. Alcohol- like liver disease in nonalcoholics: a clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988, 95:1056-1062.
41. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., et al. Tumor necrosis factor alpha promoter polymorphism and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002, 122:274-280.
42. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107:450-455.
43. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
44. Czaja A.J., Carpenter H.A., Santrach P.J., Moore S.B. Genetic predispositions for the immunological features of chronic active hepatits. Hepatology 1993, 18:816.
45. Homberg J.C., Abuaf N., Bernard O., Islam S., Alvarez F., Khalil S.H., et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of autoimmune hepatits. Hepatology 1987, 7:1330-1335.
46. Clemente M.G., Meloni A., Obermayer-Straub P., Frau F., Manns M.P., De Virgiliis S. Two Cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998, 114:324-328.
47. Blendis L., Brill S., Oren R. Hepatogenous Diabetes Reduced insulin sensitivity and increased awareness. Gastroenterology 2000, 119:1800-1802.
48. Shetty A., Wilson S., Kuo P., Laurin J.L., Howell C.D., Johnson L., et al. Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation 2000, 69:2451-2454.
49. Marchesini G., Bianchi G.P., Forlani G., Rusticali A.G., Patrono D., Capelli M., et al. Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. Dig. Dis. Sci. 1987, 32:1118-1124.
50. Buzzelli G., Chiarantini E., Cotrozzi G., Relli P., Matassi L., Romanelli R.G., et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver 1988, 8:354-359.
51. Del Vecchio Blanco C., Gentile S., Marmo R., Carbone L., Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990, 8:29-36.
52. Compean D., Jaquez-Quintana J., Gonzalez Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol 2009, 15(3):280-288.
53. Petrides A.S. Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis. Z Gastroenterol. 1999, (Suppl 1:):15-21.
54. Adami H.O., Chow W.H., Nyren O., Berne C., Linet M.S., Ekbom A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 1996, 88:1472-1477.
55. Wideroff L., Gridley G., Mellemkjaer L., Chow W.H., Linet M., Keehn S., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst. 1997, 89:1360-1365.
56. El-Serag H.B., Tran T., Everhart J.E., Kaserer K., Fiedler R., Steindl P., et al. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
57. Kazachkov Y., Yoffe B., Khaoustov V.I., Solomon H., Klintmalm G.B., Tabor E. Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. Liver 1998, 18:156-161.
58. Macdonald G.A., Greenson J.K., Saito K., Cherian S.P., Appelman H.D., Boland C.R. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology. 1998, 28(1):90-97.
59. Bianchi G., Marchesini G., Zoli M., Bugianesi E., Fabbri A., Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994, 20:119-125.
60. Harrison S.A. Liver disease in patients with diabetes mellitus. J. Clin. Gastroenterol 2006, 40:68-76.
61. Moreau R., Delegue P., Pessione F., Hillaire S., Durand F., Lebrec D., et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004 Oct, 24(5):457-464.
62. Huang M.A., Greenson J.K., Chao C., Anderson L., Peterman D., Jacobson J., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 2005, 100:1072-1081.
63. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J. Hepatol. 2005, 43:1060-1066.
64. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
65. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440-1446.
66. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
67. Nair S., Diehl A.M., Wiseman M., Farr G.H., Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 2004, 20:23-28.
68. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
69. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2004, 19:537-544.
70. Nair S, Diehl AM, Perille R. Metformin in non-alchoholic steatohepatitis: efficacy and safety: a preliminary report (Abstract). Gastroenterology2002; 122 (Suppl. 2).
71. Loomba R., Lutchman G., Kleiner D.E., Ricks M., Feld J.J., Borg B.B., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2009, 29(2):172-182.
72. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology 2005, 100(5):1082-1090.
73. de Oliveira C.P., Stefano J.T., de Siqueira E.R., Silva L.S., de Campos Mazo D.F., Lima V.M., et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatology Research 2008, 38(2):159-165.
74. Idilman R., Mizrak D., Corapcioglu D., Bektas M., Doganay B., Sayki M., et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2008, 28(2):200-208.
75. Janiec D.J., Jacobson E.R., Freeth A., Spaulding L., Blaszyk H. Histologic variation of grade and stage of nonalcoholic fatty liver disease in liver biopsies. Obesity Surgery 2005, 15(4):497-501.
76. Garinis G.A., Fruci B., Mazza A., De Siena M., Abenavoli S., Gulletta E., et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obesity 2010, 34(8):1255-1264.
77. Marlatt G.A., Larimer M.E., Mail P.D., Hawkins E.H., Cummins L.H., Blume A.W., et al. Journeys of the circle: a culturally congruent life skills intervention for adolescent Indian drinking. Alcohol Clin Exp Res 2003, 27(8):1327-1329.
78. Tiikkainen M., Ḧakkinen A.M., Korsheninnikova E., Nyman T., M̈akimattila S., Yki-J̈arvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53(8):2169-2176.
79. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135(1):100-110.
80. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Sponseller C.A., Hampton K., Bacon B.R. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 2003, 38:434-440.
81. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterology and Hepatology 2004, 2(12):1107-1115.
82. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England Journal of Medicine. 2006, 355(22):2297-2307.
83. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4):1176-1184.
84. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
85. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Basset N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Eng. J. Med. 2010, 362(18):1675-1685.
86. Lutchman G., Promrat K., Kleiner D.E., Heller T., Ghany M.G., Yanovski J.A., et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006, 4:1048-1052.
87. Petrides A.S., Vogt C., Schulze-Berge D., Matthews D., Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994, 19:616-627.
88. Sarkar A,Tiwari A, Bhasin PS, Mitra M. Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. Journal of Applied Pharmaceutical Science 2011; 11-19.
89. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:262-269.
90. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368:1696-1705.
91. Brubaker P.L. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 2010, 151:1984-1989.
92. Mudaliar S., Henry R.R. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med. 2010, 123:S19-S27.
93. Ohnuma K., Yamochi T., Hosono O., Morimoto C.C. D26 T cells in the pathogenesis of asthma. Clin Exp Immunol. 2005, 139:13-16.
94. Harada T., Kim D.W., Sagawa K., Suzuki T., Takahashi K., Saito I., et al. Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J. Gen. Virol. 1995, 76(Pt 5):1215-1221.
95. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry. 2001, 6:475-480.
96. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009, 374:39-47.
97. De Block C.E., Van Gaal L.F. GLP-1 receptor agonists for type 2 diabetes. Lancet. 2009, 374:4-6.
98. Gentile S., Turco S., Guarino G., Oliviero B., Annunziata S., Cozzolino D., et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes. Metab. 2001, 3:33-40.
99. Gentile S., Guarino G., Romano M., Alagia I.A., Fierro M., Annunziata S., et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005, 3:184-191.
100. 100-Petrides A.S. Liver disease and diabetes mellitus. Diabet Rev 1994, 2:2-18.
101. 101-Tellez-Avila F.I., Sanchez-Avila F., Garcia-Saenz-de-Sicilia M., Chavez-Tapia N.C., Franco-Guzman A.M., Lopez-Arce G., Cerda-Contreras E., Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol. 2008, 14:4771-4775.